Metastatic Breast Cancer
Conditions
Keywords
Triple Negative Breast Cancer, Cisplatin, Capecitabine
Brief summary
It is a phase II trial to explore the efficacy and safety of cisplatin plus capecitabine in anthracycline and taxane-pretreated metastatic triple negative breast cancer patients.
Detailed description
Cisplatin contained regimens have been demonstrated to be effective in metastatic triple negative breast cancer patients in some phase II clinical trials. Meanwhile, Capecitabine is also a highly effective choice for metastatic breast cancer with considerable duration of response. Combination of cisplatin and capecitabine have been proved effective in metastatic breast cancer in several phase II trials. This study is aimed to investigate the efficacy and safety of this combination in triple negative breast cancer patients.
Interventions
DRUGCisplatin/Capecitabine
Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
Sponsors
Chinese Academy of Medical Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Written and signed informed consent prior to beginning specific protocol procedures. * Pathologically confirmed Estrogen Receptor(ER), Progesterone Receptor(PR) and Human Epidermal growth factor Receptor HER-2) negative (triple negative) breast cancer and documented metastatic or locally advanced disease. Measurable disease - with at least 1 lesion measurable by radiological method * KPS\>=70 * 18 to 70 years old women * Previously treated with an anthracycline and a taxane * Hormone therapy for early-stage or metastatic breast cancer was permitted if hormonal receptor positive. * Treatment with Herceptin for early-stage or metastatic breast cancer is permitted if HER2 positive * Laboratory requirements: * Hematology Absolute neutrophil count\>=1,500 /μl; Platelets\>=100,000 /μl; Hemoglobin\>=10 g/dl * Liver function Total bilirubin\<=2 times ULN ASAT (SGOT) and ALAT (SGPT)\<=2.5 times UNL without liver metastasis or \<=5.0 times if liver metastasis Glucose\<=200 mg/dL * Renal function Serum creatinine\<=140 mol/l * Life expectancy of at least 12 weeks * Patients must be accessible for treatment and follow-up. * Patients should have recovered from the acute reversible effects of prior treatment. This generally means at least 3 weeks should have elapsed since prior chemotherapy, adjuvant or Neoadjuvant treatment. and at least 4 weeks since prior (radical) radiotherapy or major surgery
Exclusion criteria
* Women who are pregnant or breast feeding * History of brain and/or leptomeningeal metastases * Past or current history of malignant neoplasm other than breast carcinoma, except for curatively treated non melanoma skin cancer, in situ carcinoma of the cervix or other cancer curatively treated and with no evidence of disease for at least 5 years * Pre-existing neuropathy grade 1 according to the NCIC-CTC 3.0 * Psychiatric disorders or other conditions which would prevent pt. compliance * Other serious illness or medical condition: * Congestive heart failure, or unstable angina pectoris, previous history of myocardial infarction within 6 month prior to study entry, uncontrolled hypertension as determined by the Investigator or high risk uncontrolled, arrhythmia. * History of significant neurological or psychiatric disorders including psychotic disorders, dementia of seizures that would prohibit the understanding and giving of informed consent. * Active uncontrolled infection. * Unstable peptic ulcer, unstable diabetes mellitus or other contraindication for the use of Corticosteroids. * Inability to take and/or absorb oral medicine * Prior treatment with capecitabine and/or cisplatin * Concurrent treatment with other experimental drugs, or participation in another clinical trial with any investigational drug within 30 days prior to study entry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall Response Rate | 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression Free Survival | 2 years | — |
| Overall Survival | 3 years | — |
| Number and Severity of Adverse Events of Patients Enrolled in This Trial | 1 year | Number and severity of adverse events sufferred by patients who received capecitabine and cisplatin regimen. |
Countries
China
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cisplatin/Capecitabine Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity.
This is a single arm phase II clinical trial.
Cisplatin/Capecitabine: Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity | 33 |
| Total | 33 |
Baseline characteristics
| Characteristic | Cisplatin/Capecitabine |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 1 Participants |
| Age, Categorical Between 18 and 65 years | 32 Participants |
| Age, Continuous | 48 years STANDARD_DEVIATION 10 |
| Region of Enrollment China | 33 participants |
| Sex: Female, Male Female | 33 Participants |
| Sex: Female, Male Male | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 27 / 33 |
| serious Total, serious adverse events | 0 / 33 |
Outcome results
Primary
Overall Response Rate
Time frame: 6 months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cisplatin/Capecitabine | Overall Response Rate | 63.6 percentage of response |
Secondary
Number and Severity of Adverse Events of Patients Enrolled in This Trial
Number and severity of adverse events sufferred by patients who received capecitabine and cisplatin regimen.
Time frame: 1 year
Secondary
Overall Survival
Time frame: 3 years
Secondary
Progression Free Survival
Time frame: 2 years